Cancer Research AACR Conference on Molecular Diagnostics - 2008  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 21, 105-109, January 1, 1961]
© 1961 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bresnick, E.
Right arrow Articles by Hitchings, G. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bresnick, E.
Right arrow Articles by Hitchings, G. H.

Feedback Control in Ehrlich Ascites Cells*

Edward Bresnick and George H. Hitchings

( Burroughs Wellcome and Co. [U.SA.], Inc., Wellcome Research Laboratories, Tuckahos, New York)

Both carbamyl phosphate-aspartate transcarbamylase and dihydroorotase were found to be present in cell-free preparations from Ehrlich ascites tumor. Both enzymes were inhibited by various pyrimidines and derivatives thereof. Uridine-5'-phosphate was the most potent inhibitor of carbamyl phosphate-aspartate transcarbamylase, whereas fluoroorotic acid, orotic acid, and orotidine were most effective against dihydroorotase. These data demonstrate feedback control by preformed pyrimidine derivatives upon at least two of the steps which are involved in the biosynthesis of pyrimidines. Since pyrimidine analogs exhibit similar inhibitory effects, the results support the view that these antimetabolites may inhibit the biosynthesis of pyrimidines, in addition to their competitions with the products.

* Presented in part at the 51st Annual Meeting of the American Association for Cancer Research, April 8–10, 1960, Chicago, Ill.

Received 8/31/60.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1961 by the American Association for Cancer Research.